Wharton | Mr. Senior Analyst
GMAT 750, GPA 3.2
Stanford GSB | Mr. Future VC
GMAT 750, GPA 3.6
Stanford GSB | Ms. Access To Opportunities
GRE 318, GPA 2.9
Tuck | Mr. Product Marketer
GMAT 730, GPA 3.1
Wharton | Ms. Finance For Good
GMAT 730, GPA 3.7
UCLA Anderson | Mr. International PM
GMAT 730, GPA 2.3
Stanford GSB | Mr. Low GPA To Stanford
GMAT 770, GPA 2.7
USC Marshall | Mr. Low GPA High GMAT
GMAT 740, GPA 2.44
London Business School | Mr. Midwest Engineer
GMAT 750, GPA 3.69
Harvard | Mr. Policy Development
GMAT 740, GPA Top 30%
Cambridge Judge Business School | Mr. Champion Swimmer
GMAT 750, GPA 3.7
MIT Sloan | Mr. NFL Team Analyst
GMAT 720, GPA 3.8
Chicago Booth | Mr. Consulting Hopeful
GMAT 720, GPA 3.6
Kellogg | Mr. Tech Auditor
GRE 332, GPA 3.25
NYU Stern | Mr. Washed-Up Athlete
GRE 325, GPA 3.4
UCLA Anderson | Mr. Southern California
GMAT 710, GPA 3.58
Ross | Mr. Brazilian Sales Guy
GRE 326, GPA 77/100 (USA Avg. 3.0)
INSEAD | Mr. Fraud Associate
GMAT 750, GPA 8/10
Wharton | Ms. Project Mananger
GMAT 770, GPA 3.86
Chicago Booth | Mr. Average White Guy
GMAT 680, GPA 3.2
Stanford GSB | Mr. AIESEC Alumnus
GMAT 750, GPA 3.38
Kellogg | Mr. Brazilian Banker
GMAT 600, GPA 3.8
Harvard | Mr. Upward Trajectory
GMAT 720, GPA 3.3
Kenan-Flagler | Mr. Fish
GRE 327, GPA 3.733
Harvard | Mr. Community Impact
GMAT 690, GPA 3.0
IMD | Mr. Gap Year To IMD
GMAT 660, GPA 3.5
Harvard | Mr. Italian In Tokyo
GMAT (710-740), GPA 4.0

NFL Owner Kraft Gives HBS $20 Million

NFL Owner Robert Kraft

NFL Owner Robert Kraft

As Harvard Business School MBA and corporate titan Robert Kraft’s wife lay dying of cancer, Kraft frequently consulted with former HBS professor Eric Lander, founding director of the biomed-focused Harvard/MIT Broad Institute. Myra Kraft passed away in 2011, but the relationship that grew between her husband and Lander has now led to a major gift to HBS, an endowment intended to deliver a boost to a cutting-edge field of medicine – and bring new opportunities for MBAs.

The school announced today (Nov. 18) a $20 million endowment to HBS from the Robert and Myra Kraft Foundation, to create the Kraft Endowment for Advancing Precision Medicine. Precision medicine, also called “personalized medicine,” combines a patient’s genetic, lifestyle, and environment information to enable targeted, individualized medical treatment.

“For all diseases this is the new approach that virtually all big pharma and certainly startup R&D efforts are going after – targeted therapies, not large broad-based therapies,” says HBS management professor Richard Hamermesh. “Most drugs work for no more than 60% of the people that take them. Diseases and humans all different. It’s not like one size serves all.”

Harvard Business School - Ethan Baron photo

Harvard Business School – Ethan Baron photo


The donation pledge brings Harvard closer to the goal of a capital campaign announced last year to bring in $1 billion over five years. By the end of this past June, HBS had raised $861 million, with $261 million of that brought in after the official April 2014 announcement.

Billionaire donor Kraft, who received his HBS MBA in 1965 and owns the New England Patriots, wants to see results from his donation as quickly as possible, Hamermesh says. “He doesn’t want more people suffering the same fate that his wife did,” Hamermesh adds.

Precision medicine is used extensively in cancer treatment. “In most cases, tumors are (genetically) sequenced so you understand exactly what the genetic mutations are in a particular cancer, and then you treat the mutations,” Hamermesh says. “In time, cancers will be known not so much as lung cancer or liver cancer or whatever, but they’ll be known by the mutations in the genetic pathways that are being disrupted.”

Genetics-based precision treatment is also used for cystic fibrosis, which is caused by irregularities in a single gene. Precision medicine identified three different mutations, and there are treatments for two of them, meaning that about 65% of U.S. children diagnosed with the disease will be treated as long as they live, but never develop symptoms, Hamermesh says. AIDS, too, is addressed with precision medicine – the virus is sequenced to identify mutations, and drug cocktails prescribed based on which mutations are present.


Barriers to expansion of precision medicine are 70% business problems and only 30% science problems, Hamermesh says. “You need lots of data that organizations and institutions need to share to do the numerical analysis linking aberrations and mutations in genes to specific diseases,” he says. “That’s where the B-school comes in.